Sublingual immunotherapy: World Allergy Organization position paper 2013 update
- PMID: 24679069
- PMCID: PMC3983904
- DOI: 10.1186/1939-4551-7-6
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Abstract
We have prepared this document, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update", according to the evidence-based criteria, revising and updating chapters of the originally published paper, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2009", available at http://www.waojournal.org. Namely, these comprise: "Mechanisms of sublingual immunotherapy;" "Clinical efficacy of sublingual immunotherapy" - reporting all the data of all controlled trials published after 2009; "Safety of sublingual immunotherapy" - with the recently published Grading System for adverse reactions; "Impact of sublingual immunotherapy on the natural history of respiratory allergy" - with the relevant evidences published since 2009; "Efficacy of SLIT in children" - with detailed analysis of all the studies; "Definition of SLIT patient selection" - reporting the criteria for eligibility to sublingual immunotherapy; "The future of immunotherapy in the community care setting"; "Methodology of clinical trials according to the current scientific and regulatory standards"; and "Guideline development: from evidence-based medicine to patients' views" - including the evolution of the methods to make clinical recommendations.Additionally, we have added new chapters to cover a few emerging crucial topics: "Practical aspects of schedules and dosages and counseling for adherence" - which is crucial in clinical practice for all treatments; "Perspectives and new approaches" - including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single products. Furthermore, "Raising public awareness about sublingual immunotherapy", as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion, are also reported in detail.
Figures
Similar articles
-
Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.World Allergy Organ J. 2020 Aug 21;13(8):100444. doi: 10.1016/j.waojou.2020.100444. eCollection 2020 Aug. World Allergy Organ J. 2020. PMID: 32884611 Free PMC article. Review.
-
[New administration routes for immunotherapy].Allergol Immunopathol (Madr). 2000 May-Jun;28(3):93-102. Allergol Immunopathol (Madr). 2000. PMID: 10867377 Review. Spanish.
-
30 years of sublingual immunotherapy.Allergy. 2020 May;75(5):1107-1120. doi: 10.1111/all.14113. Epub 2019 Dec 20. Allergy. 2020. PMID: 31715001 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Immunotherapy (oral and sublingual) for food allergy to fruits.Cochrane Database Syst Rev. 2015 Nov 9;2015(11):CD010522. doi: 10.1002/14651858.CD010522.pub2. Cochrane Database Syst Rev. 2015. PMID: 26558953 Free PMC article. Review.
Cited by
-
Effect of house dust mite sublingual immunotherapy in patients with adult atopic dermatitis with rhinitis.Future Sci OA. 2024 Dec 31;10(1):2419779. doi: 10.1080/20565623.2024.2419779. Epub 2024 Nov 14. Future Sci OA. 2024. PMID: 39539183 Free PMC article.
-
V Brazilian Consensus on Rhinitis - 2024.Braz J Otorhinolaryngol. 2024 Sep 7;91(1):101500. doi: 10.1016/j.bjorl.2024.101500. Online ahead of print. Braz J Otorhinolaryngol. 2024. PMID: 39388827 Free PMC article. Review.
-
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.J Pers Med. 2024 Aug 12;14(8):854. doi: 10.3390/jpm14080854. J Pers Med. 2024. PMID: 39202045 Free PMC article.
-
Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data.World Allergy Organ J. 2024 Jun 25;17(7):100924. doi: 10.1016/j.waojou.2024.100924. eCollection 2024 Jul. World Allergy Organ J. 2024. PMID: 39035788 Free PMC article.
-
Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI).J Allergy Clin Immunol Glob. 2024 May 18;3(3):100281. doi: 10.1016/j.jacig.2024.100281. eCollection 2024 Aug. J Allergy Clin Immunol Glob. 2024. PMID: 38975257 Free PMC article. Review.
References
-
- Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;7:559–566. doi: 10.1016/j.jaci.2011.06.022. - DOI - PubMed
-
- Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;7:717–725. doi: 10.1016/j.jaci.2011.12.973. e715. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
